Femta Pharmaceuticals
Biotechnology company that develops protein therapeutics
About Femta Pharmaceuticals
Femta Pharmaceuticals Inc. operated as a clinical-stage biopharmaceutical company with a focus on developing therapeutic monoclonal antibodies. Founded in 2008 and based in San Diego, California, the company directed its efforts toward treatments for inflammation and autoimmune diseases.
The company's core activity revolved around its drug pipeline, which included several candidates targeting inflammatory proteins. Its lead drug, FM-101, was a humanized monoclonal antibody designed to inhibit interleukin-6 (IL-6), a protein implicated in conditions like rheumatoid arthritis. In August 2011, Femta submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to commence a Phase I clinical trial for FM-101 in patients with active rheumatoid arthritis. Preclinical and toxicology studies had previously indicated the drug's effectiveness and safety. To support its development and manufacturing, Femta entered into an agreement with Lonza Group in late 2009 for the cGMP manufacturing of FM101. Other drug candidates in its pipeline included FM-202, targeting IL-12R and IL-23 for psoriasis, and FM-303, an IL-23 inhibitor for inflammatory bowel diseases.
From a financial perspective, Femta Pharmaceuticals successfully raised a total of $3.7 million over three funding rounds between July 2009 and October 2010. These included two seed rounds totaling $1.5 million and a subsequent Series A round of $2.2 million in October 2010, with LVP participating as an investor. Public SEC filings correspond with these funding activities, showing documents filed in July 2009, November 2009, and July 2010. The company was eventually acquired by Biotech Investment Group and is now considered dissolved or deadpooled.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2010 | $22M | $88M | Latterell Venture Partners | — |
| SEED✓Equity / VC | Nov 2009 | $500K | $2M | Latterell Venture Partners | — |
Growth signals
Latest recorded traffic for Femta Pharmaceuticals is 0 monthly website visits. Femta Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Femta Pharmaceuticals in the San Diego ecosystem
The Femta Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Latterell Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Femta Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Femta Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.




